Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Celgene : Nimbus Therapeutics Reaches Summit For Deal With Celgene

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 02:11pm CET

Today Nimbus and Celgene announced a significant partnership focused on autoimmune and inflammatory diseases.

The alliance includes two pre-clinical autoimmune-focused programs in various stages of drug discovery. The most advanced program is a highly selective inhibitor of Tyk2, an immunokinase of the JAK family, which plays a central role in the inflammatory response (triggering IL-23, IL-12, and Type-I interferon). Human genetics, including both loss- and gain-of-function changes, validate Tyk2 as perhaps the most critical JAK family member to attenuate in many major autoimmune diseases. Given Tyk2s proximal role in regulating both Th17 and Th1 responses, the target is one of the most sought after by immunology R&D groups. BMS has a competing Tyk2 program in early clinical development. The figure below illustrates why a safe, well tolerated oral Tyk2 inhibitor has enormous potential: it would not only replicate the efficacy of multiple blockbuster mAbs, but also explore a large number of other autoimmune diseases beyond psoriasis and RA.

Another program in this alliance with Celgene is a small molecule, non-nucleotide antagonist of STING, a pattern recognition receptor in innate immune responses. In I/O today, STING agonists are believed to be of value in turning up the immune response to tumors; this antagonist program is aimed at doing the opposite to turn down inflammation in the context of autoimmunity, and STING activation has been implicated in the pathogenesis of diseases like lupus.

This deal, dubbed Project Everest as a reference to Celgenes corporate headquarters in Summit, NJ, was the product of over a years worth of active dialogues between the two leadership teams. Were excited to work with Celgene on these programs as they are great fits with their growing I&I franchise.

Beyond affirming the compelling science underpinning these programs, this deal provides further validation for the Nimbus Therapeutics tripartite value creation approach: cutting-edge computational drug discovery; globally-distributed, virtually-integrated operations; and, a novel asset-centric corporate structure LLC.

These three elements were central to our investment thesis when we seeded the startup in 2009, and again when we came out of stealth mode in spring 2011, culminating in our Series A round. Over the past six years, theres been several posts on Nimbus model and success (including early deal-making with the LLC structure, running virtual companies and the Uber-like disruption in this operating configuration, etc.). But to sum up these three pillars briefly:

Compelling scientific platform. Nimbus has a privileged relationship with our computational partner and co-founder, Schrdinger. Early on we were inspired by new approaches to understanding solvent energetics (unstable waters), but this relationship has grown into next generation techniques around FEP of ligands and proteins and better force fields. Further, we bring a host of other key technologies to bear, like crystallography, ADME prediction, and proprietary in silico designed molecular scaffolds, to name a few. On its own, technology isnt a viable standalone solution, as described in my cautionary post on Four Decades Of Hacking Biotech And Yet Biology Still Consumes Everything. Integration of this powerful technology suite within a team of bona fide drug hunters, who possess both a nose and judgment for drug discovery, is the critical ingredient in making this work.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
02/20CELGENE CORP /DE/ : Entry into a Material Definitive Agreement, Creation of a Di..
02/20Celularity Announces $250M in Funding to Deliver Treatments for Cancer Inflam..
02/20CELGENE : Reports Positive Data on Dermatology Drug Otezla
02/20CELGENE : reveals strong P3 Otezla data in rare inflammatory condition
02/19CELGENE CORPORATION : Elects John Weiland to Its Board of Directors
02/17CELGENE : OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in..
02/17CELGENE : OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in..
02/17CELGENE : OTEZLA (Apremilast) Phase II Data Showed Clinically Meaningful Improve..
02/16CELGENE : Announces Additional $5 Billion Share Repurchase Authorization
02/16AGIOS PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2017 Financial Resu..
More news
News from SeekingAlpha
02/20BIOTECHS : Still Well Placed For More Gains 
02/20Celgene's Otezla reduces oral ulcers in late-stage study 
02/19Healthcare In Transition 
02/19YOUR DAILY PHARMA SCOOP : AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Ce.. 
02/19VALUATION DASHBOARD : Healthcare - Update 
Financials ($)
Sales 2018 14 810 M
EBIT 2018 8 539 M
Net income 2018 5 625 M
Finance 2018 346 M
Yield 2018 -
P/E ratio 2018 13,62
P/E ratio 2019 11,25
EV / Sales 2018 4,81x
EV / Sales 2019 3,88x
Capitalization 71 652 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 125 $
Spread / Average Target 32%
EPS Revisions
Mark J. Alles Chairman & Chief Executive Officer
Scott Andrew Smith President & Chief Operating Officer
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359